Hospital Universitario Araba-ko ikertzaileekin lankidetzan egindako argitalpenak (34)

2023

  1. Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain

    European Journal of Haematology, Vol. 111, Núm. 3, pp. 485-490

  2. Spanish cardiac catheterization and coronary intervention registry. 32nd official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2022)

    Revista Espanola de Cardiologia, Vol. 76, Núm. 12, pp. 1021-1031

2022

  1. ABCL-297 Hemophagocytic Lymphohistiocytosis Singularity: A Multicenter Retrospective Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S369-S370

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)

    PLoS ONE, Vol. 16, Núm. 9 September

  2. Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  3. Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival

    Journal of the American Heart Association, Vol. 10, Núm. 2, pp. 1-21

  4. Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study

    Journal of Clinical Oncology, Vol. 39, Núm. 28, pp. 3118-3127

2020

  1. Benefit of primary percutaneous coronary interventions in the elderly with ST segment elevation myocardial infarction

    Open Heart, Vol. 7, Núm. 2

  2. Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review

    Reumatologia Clinica, Vol. 16, Núm. 5P1, pp. 324-332

  3. Impact of COVID-19 on ST-segment elevation myocardial infarction care. The Spanish experience

    Revista Espanola de Cardiologia, Vol. 73, Núm. 12, pp. 994-1002

2018

  1. A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: A multicenter, retrospective analysis by the Spanish GELTAMO group

    American Journal of Hematology, Vol. 93, Núm. 7, pp. 867-873

  2. Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project

    Reumatologia Clinica, Vol. 14, Núm. 2, pp. 90-96

  3. Recommendations for the use of parenteral methotrexate in rheumatic diseases

    Reumatologia Clinica, Vol. 14, Núm. 3, pp. 142-149

  4. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: A multicenter, double-blind, randomized clinical trial

    European Heart Journal, Vol. 39, Núm. 15, pp. 1255-1264

  5. Treatment Design and Rationale for a Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for SCLC: PREMER Trial on Behalf of the Oncologic Group for the Study of Lung Cancer/Spanish Radiation Oncology Group-Radiation Oncology Clinical Research Group

    Clinical Lung Cancer, Vol. 19, Núm. 5, pp. e693-e697

2017

  1. Chronic lymphocytic leukemia with isochromosome 17q: An aggressive subgroup associated with TP53 mutations and complex karyotypes

    Cancer Letters, Vol. 409, pp. 42-48

  2. Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group

    Leukemia Research, Vol. 63, pp. 85-89

2016

  1. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations

    Oncotarget, Vol. 7, Núm. 49, pp. 80916-80924